内容紹介
Summary
Regorafenib is widely used for patients with metastatic colorectal cancer, following disease progression with standard therapies. However, regorafenib has severe toxicities; therefore, careful monitoring and treatment are necessary. Several studies have investigated the efficacy of initial dose reductions. We started regorafenib doses from 80 mg, with a duration of 1 week on and 1 week off, after which we gradually increased the dosage and duration. From September 2015 to March 2017, we treated 7 consecutive patients who received regorafenib following standard chemotherapy for metastatic colorectal cancer. The average age was 73 years and average BMI was 23.3. The average total dose was 15,960(2,240-28,000)mg, and the average treatment duration was 243(50-379)days. The mean survival from the start of regorafenib was 399(median 407, 262-622)days. Adverse events of Grade 3 or higher were observed in 1 patient(14%).
要旨
レゴラフェニブは切除不能結腸直腸癌で使用されているが,副作用の発現頻度が高く注意深い観察や処置が必要な薬剤である。これまで減量投与の有効性は報告されているが,われわれは80 mgへの減量と1週投与1週休薬の期間短縮を加えた投与法で開始し,徐々に増量と期間延長を行った。2015年9月～2017年3月までに切除不能遠隔転移,再発を認めた結腸直腸癌に対し,標準化学療法後にレゴラフェニブを投与した7症例について検討を行った。平均年齢73歳,平均BMI 23.3,平均総投与量15,960(2,240～28,000)mg,平均投与期間は243(50～379)日であった。投与開始からの平均生存期間は399(中央値407,262～622)日であった。Grade 3以上の副作用は1症例(14%)に認められた。低い副作用の発生割合と長期の生存を認めたので報告する。
目次
Regorafenib is widely used for patients with metastatic colorectal cancer, following disease progression with standard therapies. However, regorafenib has severe toxicities; therefore, careful monitoring and treatment are necessary. Several studies have investigated the efficacy of initial dose reductions. We started regorafenib doses from 80 mg, with a duration of 1 week on and 1 week off, after which we gradually increased the dosage and duration. From September 2015 to March 2017, we treated 7 consecutive patients who received regorafenib following standard chemotherapy for metastatic colorectal cancer. The average age was 73 years and average BMI was 23.3. The average total dose was 15,960(2,240-28,000)mg, and the average treatment duration was 243(50-379)days. The mean survival from the start of regorafenib was 399(median 407, 262-622)days. Adverse events of Grade 3 or higher were observed in 1 patient(14%).
要旨
レゴラフェニブは切除不能結腸直腸癌で使用されているが,副作用の発現頻度が高く注意深い観察や処置が必要な薬剤である。これまで減量投与の有効性は報告されているが,われわれは80 mgへの減量と1週投与1週休薬の期間短縮を加えた投与法で開始し,徐々に増量と期間延長を行った。2015年9月～2017年3月までに切除不能遠隔転移,再発を認めた結腸直腸癌に対し,標準化学療法後にレゴラフェニブを投与した7症例について検討を行った。平均年齢73歳,平均BMI 23.3,平均総投与量15,960(2,240～28,000)mg,平均投与期間は243(50～379)日であった。投与開始からの平均生存期間は399(中央値407,262～622)日であった。Grade 3以上の副作用は1症例(14%)に認められた。低い副作用の発生割合と長期の生存を認めたので報告する。